StemCell Therapy

SAN DIEGO, January 31, 2020Human Longevity, Inc.(HLI),an innovator in providing data-driven health intelligence and precision health to physicians and patients, announced the publication of a ground-breaking study in the journalProceedings of the National Academy of Sciences(PNAS). The study titled, Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging, showed thatby integrating whole-genome sequencing with advanced imaging and blood metabolites, clinicians identified adults at risk for key health conditions.Data from 1190 self-referred individuals evaluated with HLIs multi-modal precision health platform, Health Nucleus, show clinically significant findings associated with age-related chronic conditions including cancer, heart disease, diabetes, chronic liver disease, and neurological disorders leading causes of pre-mature mortality in adults.

The goal of precision medicine is to provide a path to assist physicians in achieving disease prevention and implementing accurate treatment strategies, said C. Thomas Caskey, MD, FACP, FACMG, FRSC, chief medical officer for Human Longevity, Inc., lead author of the study, and a member of the National Academy of Sciences. Our study showed that by employing a holistic and data-driven health assessment for each individual, we are able to achieve early disease detection in adults.

Study highlights include:

This study shows that the definition of healthy may not be what we think it is and depends upon a comprehensive health evaluation, said J. Craig Venter, PhD, founder, Human Longevity, Inc. and a member of the National Academy of Sciences. The data underscore Human Longevitys innovative approach to helping clinicians with early detection and personalized treatments, potentially achieving better health outcomes for patients.

Our traditional approach to the annual health assessment has been very superficial and will need to be replaced by data-driven measures that will be made possible as costs continue to decline for whole- genome sequencing, advanced imaging, especially MRI, and specialized blood analytics, said David Karow, MD, PhD, president and chief innovation officer, Human Longevity, Inc.

ABOUT THE STUDY

The study cohort was composed of 1190 self-referred participants who enrolled at Health Nucleuswith a median age of 54 y (range 20 to 89+ y, 33.8% female, 70.6% European). A multidisciplinary team, including cardiologists, radiologists, primary care physicians, clinical geneticists, genetic counselors, and research scientists, integrated deep phenotype data with genome data for each study participant.Participants were enrolled in the study between September 2015 and March 2018.

ABOUT THE HEALTH NUCLEUS

Health Nucleus is Human Longevitys premier health intelligence platform utilizing state-of-the-art technology to provide an assessment of current and future risk for cardiac, oncologic, metabolic, and cognitive diseases and conditions. This is provided through a proprietary, multi-modal approach, integrating data from an individuals whole-genome sequencing, brain and body MRI imaging, cardiac CT calcium scan, metabolomics, advanced blood test, and more. The health assessment is conducted at Human Longevitys Health Nucleus precision medicine center in La Jolla, California.For more information, visitwww.healthnucleus.com.

ABOUT HUMAN LONGEVITY

Human Longevity, Inc. (HLI)is a genomics-based,health intelligence companyempowering proactive healthcare and enabling a life better lived. HLIs business focus includes the Health Nucleus, a genomic-powered, precision medicine center which uses whole-genome sequencing analysis, advanced imaging, and blood analytics, to deliver the most complete picture of individual health. For more information, visitwww.humanlongevity.com.

# # #

For more information, contact: Debbie Feinberg, VP of Marketing, Human Longevity, Inc., 858-864-1058,dfeinberg@humanlongevity.com

See the original post:
Human Longevity's Largest Study of its Kind Shows Early Detection of Disease and Disease Risks in Adults - Cath Lab Digest

This entry was posted on February 1, 2020 at 4:46 am and is filed under Genetic medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |